SIMCERE PHARMA: The new drug application (NDA) for Maribavir granules has been accepted by the National Medical Products Administration
I'm PortAI, I can summarize articles.
SIMCERE PHARMA's new drug application (NDA) for the anti-influenza drug Madaxanovir granules, in collaboration with Jiaxing Andikang Biotechnology Co., Ltd., has been accepted by the National Medical Products Administration. This drug is used to treat uncomplicated influenza A and B in children aged 2 to 11 years and is China's first innovative antiviral drug for children, with good safety and multiple clinical advantages
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments